Cromos Pharma, where the patients are

GlaxoSmithKline

Icon’s Firecrest training recognized by TransCelerate BioPharma

Monday, April 14, 2014 10:13 AM

Icon,a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has announced that its Firecrest training meets TransCelerate BioPharma’s minimum criteria for International Conference on Harmonization Good Clinical Practice (ICH/GCP) training.

More... »

CRF Health eCOA webinar series

MD Anderson, GSK form immunotherapy collaboration

Thursday, April 10, 2014 02:00 PM

The University of TexasMD Anderson Cancer Center has formed a research alliance with global pharmaceutical developer GlaxoSmithKline (GSK) to strengthen its efforts in advancing therapies that train the body's immune system to combat cancer.

More... »


GlaxoSmithKline invests in Africa

Wednesday, April 2, 2014 01:54 PM

GlaxoSmithKline has announced a series of new investments in sub-Saharan Africa designed to address pressing health needs and contribute to long-term business growth. GSK CEO Sir Andrew Wittyhasset out the company’s intent to partner with governments of African countries to help stimulate more research into chronic diseases, increase capacity by localizing medicines supply and strengthen healthcare infrastructure.

More... »

GSK, EMBL-EBI, Wellcome Trust form ‘big data’ research initiative

Friday, March 28, 2014 03:09 PM

A pioneering public-private research initiative between GlaxoSmithKline, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute has formed to harness the power of “big data” and genome sequencing to improve the success rate for discovering new medicines. The new Center for Therapeutic Target Validation (CTTV) will aim to address a wide range of human diseases and will share its data openly in the interests of accelerating drug discovery.

More... »

Antibacterial drugs market to top $45B globally in 2019

Monday, March 24, 2014 02:48 PM

According to a new market report from Transparency Market Research, a global market intelligence company, the global antibacterial drugs market was valued at $43.55 billion in 2012 and is expected to grow at a CAGR of 0.3% from 2013 to 2019, to reach an estimated value of $45.09 billion in 2019.

More... »

CluePoints expands global team

Friday, February 28, 2014 11:36 AM

CluePoints, a provider of Risk-Based Monitoring (RBM) solutions for clinical trials, has announced three new appointments to its global team. John Colby and Elizabeth Polvent join the company's U.S business development team, fulfilling a key element in its strategy for growth, while CluePoints also welcomes Jean Stéphenne, president of the board of directors of GlaxoSmithKline Biologicals, as a member of its board.

More... »

GSK, Uppsala launch $140.6M European program targeting novel antibiotics

Wednesday, February 12, 2014 01:20 PM

Over 30 European universities, research institutes and companies, led by GlaxoSmithKline and Uppsala University, are joining forces in a six-year program supported by the Innovative Medicines Initiative (IMI) to develop novel antibiotics against Gram-negative pathogens in a project called ENABLE (European Gram-Negative Antibacterial Engine), including open calls for candidates outside the consortium.

More... »

Report: Absence of 2014 blockbuster drug launches puts R&D productivity at risk

Monday, February 10, 2014 09:54 AM

The past two years have brought a surge of R&D productivity, driving investor confidence and increasing market performance, but 2014 looks to tell a different tale according to a new report from EP Vantage, a source of life science market intelligence and analysis.

More... »

Report: Pharmaceutical firms are humanizing their brands

Thursday, February 6, 2014 11:45 AM

By 2018, it is estimated the global pharmaceutical market will be worth more than $1.3 trillion. To corner their share of profits, established drug companies have to fight fierce competition from generic products, adhere to stringent government regulations and sway a consumer base that is better informed than ever before.

More... »

NIH, industry and nonprofits join forces to speed validation of disease targets

Wednesday, February 5, 2014 01:02 PM

The National Institutes of Health, 10 biopharmaceutical companies and several nonprofit organizations have launched an unprecedented partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs